In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Effects of statins on major adverse cardiovascular events in patients with ischemic chronic heart failure with reduced ejection fraction and renal dysfunction

Session Poster Session 3

Speaker Dmytro Lashkul

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : D Lashkul (Zaporizhzhya,UA)

Authors:
D Lashkul1 , 1Zaporizhzhya State Medical University - Zaporizhzhya - Ukraine ,

Citation:

The aim of the study to investigate the effect of different doses of statins on long-term prognosis in patients with ischemic chronic heart failure (CHF) with reduced ejection fraction (EF) and renal dysfunction (RD).

Materials and methods. The study involved 140 patients (114 (81.4 %) men) with ischemic CHF, mean age 60 [54-68] years. 2 functional class (FC) of chronic heart failure was diagnosed in 27 (19.3 %) patients, 3 FC - in 98 (70 %) patients. Prior myocardial infarction was in 106 (75,7 %) patients. The glomerular filtration rate (eGFR) was calculated using the formula MDRD (Modification of Diet in Renal Disease). Mean GFR was 70.2±15.5 ml/min/1.73cm2, mean ejection fraction 34.7±7.2 %. Therapy included: ACE inhibitors/ARBs (90 %), beta blockers (94.3 %), diuretics (87.8 %), antagonists mineralocorticoid receptor (75 %), antiplatelet agents (70.7 %), calcium antagonists (14.3 %), amiodarone (18.6 %), ivabradine (15 %). Statins received 118 (84.3 %) patients in doses that meet mild and moderate intensity lowering low-density lipoprotein cholesterol (mean dose of atorvastatin amounted to 21.9 mg, rosuvastatin - 12.9 mg). The period of follow-up was 3 years. As clinical endpoints were considered all fatal and non-fatal atherothrombotic events, including re-infarction, ischemic stroke, sudden cardiac death, heart failure and all cases of hospitalization due to this reason, registered within 3 years after signing informed consent. The cumulative survival curves were constructed with the use of the Kaplan-Meier method and groups were compared with the log-rank test.

Results. Analysis of the observations showed that adverse cardiovascular events during the observation period occurred in 92 (65.7 %) patients, among them - the fatal re-infarction in 8 (8.7 %), sudden cardiac death in 25 (27.2 %) patients, 53 patients (57.6 %) was hospitalized due to HF decompensation, 4 patients (4.3 %) reported non-fatal re-infarction, 2 (2.2 %) patients non-fatal stroke. Found that inclusion statins in the standard pharmacological therapy of ischemic CHF patients with reduced EF and RD reduces the risk of a cumulative endpoint by 51% (HR 0.49; 95 % CI 0.26-0.91; p=0.02), mainly due to reduction of episodes of hospitalization due to decompensation of HF (HR 0.32; 95 % CI 0.14-0.72; ?<0.01). The positive effect was independent of the intensity statin therapy (HR 0.96; 95 % CI 0.52-1.78; p=0.91), but among the statins atorvastatin had the advantage (HR 0.37; 95 % C? 0.21-0.69; ?<0.001).

Conclusions. The inclusion of statins in the standard pharmacological therapy of patients with ischemic CHF with reduced left ventricular EF and renal dysfunction significantly reduces the risk of cumulative endpoint, mainly due to the prevention of hospitalizations regarding decompensation of HF. Regimen of administration of statins (mild and moderate intensity) did not significantly affect the risk of cardiovascular events.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are